Skip to main content

Table 3 Cardiovascular events of MSU crystal exposed and unexposed by subgroups

From: Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients? A Danish cohort study

 

MSU crystals

No crystals

Hazard ratio (95 % CI)

(events / person-years)

(events / person-years)

PS adjusted*

All

46 / 1026

34 / 1009

0.86 (0.52–1.43)

Age <60

14 / 698

4 / 577

1.31 (0.42–4.15)

Age 60–79

15 / 240

20 / 370

0.79 (0.36–1.76)

Age 80+

17 / 88

10 / 62

0.79 (0.31–1.97)

Male

40 / 951

31 / 896

0.82 (0.47–1.41)

Female

6 / 75

3 / 113

1.87 (0.33–10.57)

No previous APTC

30 / 950

24 / 958

0.92 (0.48–1.74)

Only previous APTC

16 / 76

10 / 51

0.73 (0.28–1.94)

CKD 4 + 5

8 / 41

3 / 74

2.57 (0.57–11.55)

CKD 3

18 / 190

11 / 164

1.24 (0.54–2.86)

CKD 2

8 / 580

19 / 611

0.35 (0.13–0.89)

CKD 1

10 / 163

1 / 131

3.72 (0.44–31.23)

DM

11 / 103

9 / 102

0.79 (0.28–2.23)

No DM

35 / 923

25 / 907

0.93 (0.51–1.69)

Hypertension

22 / 245

10 / 214

1.69 (0.76–3.78)

Normotensive

24 / 781

24 / 795

0.64 (0.32–1.26)

  1. APTC AntiPlatelet Trialists’ Collaboration, CI confidence interval, CKD chronic kidney disease stages, DM diabetes mellitus, MSU monosodium urate, PS propensity score
  2. *All subgroups are PS adjusted. The no-crystal group was set as reference